Truepill vs Altria

Side-by-side comparison of AI visibility scores, market position, and capabilities

Altria leads in AI visibility (90 vs 24)

Truepill

EmergingHealthcare

Digital Pharmacy Infrastructure

Acquired by LetsGetChecked August 2024 for $525M; $322M total funding; $66.2M Series D August 2023; $1.6B valuation; 1M+ prescriptions processed

AI VisibilityBeta
Overall Score
D24
Category Rank
#1 of 1
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
28
Perplexity
20
Gemini
28

About

Truepill is a digital pharmacy infrastructure provider that enables healthcare companies, telehealth platforms, and retailers to offer pharmacy services through white-label fulfillment and technology solutions. The company serves digital health startups, health systems, retailers, and telemedicine providers who want to integrate prescription fulfillment into their offerings without building pharmacy infrastructure. Truepill operates a nationwide network of licensed pharmacies and provides end-to-end pharmacy services including prescription processing, medication dispensing, and direct-to-patient delivery.

Full profile

Altria

LeaderConsumer Goods

Enterprise

Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.

AI VisibilityBeta
Overall Score
A90
Category Rank
#83 of 290
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
97
Gemini
99

About

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.

Full profile

AI Visibility Head-to-Head

24
Overall Score
90
#1
Category Rank
#83
79
AI Consensus
58
stable
Trend
stable
28
ChatGPT
84
20
Perplexity
97
28
Gemini
99
23
Claude
86
24
Grok
87

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.